116 related articles for article (PubMed ID: 10683123)
1. Report examines strategies for reducing breast cancer risk.
Miller JL
Am J Health Syst Pharm; 1999 Jul; 56(13):1298. PubMed ID: 10683123
[No Abstract] [Full Text] [Related]
2. Raloxifene to prevent postmenopausal osteoporosis.
Drug Ther Bull; 1999 May; 37(5):33-6. PubMed ID: 10563056
[TBL] [Abstract][Full Text] [Related]
3. [What do we think about selective estrogen receptor modulators?].
Cortet B
Rev Med Interne; 2001 Dec; 22(12):1173-6. PubMed ID: 11794886
[No Abstract] [Full Text] [Related]
4. Designer estrogens.
Jordan VC
Sci Am; 1998 Oct; 279(4):60-7. PubMed ID: 9768522
[No Abstract] [Full Text] [Related]
5. Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow.
Jordan VC
J Natl Cancer Inst; 1998 Jul; 90(13):967-71. PubMed ID: 9665143
[No Abstract] [Full Text] [Related]
6. Raloxifene examined for breast cancer prevention.
Young D
Am J Health Syst Pharm; 2007 Sep; 64(17):1774. PubMed ID: 17724350
[No Abstract] [Full Text] [Related]
7. Selective estrogen receptor modulators.
Kearney CE; Purdie DW
Climacteric; 1998 Jun; 1(2):143-7. PubMed ID: 11907917
[No Abstract] [Full Text] [Related]
8. [Treatment of postmenopausal osteoporosis with raloxifene].
Fedelesova V; Chylova K; Dzurik
Bratisl Lek Listy; 2000; 101(9):527-8. PubMed ID: 11187059
[TBL] [Abstract][Full Text] [Related]
9. Prevention of osteoporosis and uterine effects in post-menopausal women taking raloxifene for 5 years.
Api M
Menopause; 2004; 11(4):495-6; author reply 496-7. PubMed ID: 15243288
[No Abstract] [Full Text] [Related]
10. Anti-estrogens come of age: a pioneer looks back.
Nelson NJ
J Natl Cancer Inst; 1998 May; 90(9):646-7. PubMed ID: 9586657
[No Abstract] [Full Text] [Related]
11. ERT, HRT, raloxifine, calcitonin, or bisphosphonates for osteoporosis.
Curtiss FR
J Manag Care Pharm; 2003; 9(2):178-81. PubMed ID: 14613350
[No Abstract] [Full Text] [Related]
12. Breast cancer hopes.
Zurlinden J
Nurs Spectr (Wash D C); 1998 Jun; 8(11):17-8. PubMed ID: 10542741
[No Abstract] [Full Text] [Related]
13. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
[TBL] [Abstract][Full Text] [Related]
14. How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?
Delmas PD
Bone; 2000 Jul; 27(1):1-3. PubMed ID: 10865202
[No Abstract] [Full Text] [Related]
15. Sex steroid analogs.
Christiansen C
Osteoporos Int; 1999; 9 Suppl 2():S62-5. PubMed ID: 10525728
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study.
Kanis JA; Borgström F; Johnell O; Oden A; Sykes D; Jönsson B
Osteoporos Int; 2005 Jan; 16(1):15-25. PubMed ID: 15672210
[TBL] [Abstract][Full Text] [Related]
17. Raloxifene vs tamoxifen.
Goldstein SR
JAMA; 2007 Jan; 297(3):263-4; author reply 264. PubMed ID: 17227974
[No Abstract] [Full Text] [Related]
18. In the clinic. Breast cancer screening and prevention.
Nattinger AB
Ann Intern Med; 2010 Apr; 152(7):ITC41. PubMed ID: 20368645
[No Abstract] [Full Text] [Related]
19. [Raloxifene - an unexploited possibility of prevention and treatment of postmenopausal osteoporosis].
Štěpán J; Rosa J; Pavelka K
Vnitr Lek; 2016; 62(10):781-788. PubMed ID: 27900864
[TBL] [Abstract][Full Text] [Related]
20. [Specific estrogen receptor modulators (SERMs)].
Trémollières F; Lopes P
Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
